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Abstract: Picolinic Acid is an endogenous metabolite of L-tryptophan (TRP) that has been reported to possess a wide range 
of neuroprotective, immunological, and anti-proliferative affects within the body. However the salient physiological function 
of this molecule is yet to be established. The synthesis of picolinic acid as a product of the kynurenine pathway (KP) sug-
gests that, similar to other KP metabolites, picolinic acid may play a role in the pathogenesis of infl ammatory disorders 
within the CNS and possibly other organs.
In this paper we review the limited body of literature dealing with the physiological actions of picolinic acid in the CNS 
and its associated synthesis via the kynurenine pathway in health and disease. Discrepancies and gaps in our current knowl-
edge of picolinic acid are identifi ed highlighting areas of research to promote a more complete understanding of its endog-
enous function in the brain.
Background
Picolinic Acid (PIC) is a six-member ring structure compound (Fig. 1) that has been detected in a variety 
of biological mediums including, cell culture supernatants, blood serum1 cerebrospinal fl uid (CSF),2 
human milk, pancreatic juice and intestinal homogenates.3
PIC is synthesised from L-tryptophan (TRP) via a sequent side branch of the kynurenine pathway 
(KP) involving enzymatic shunting of an aminocarboxysemialdehyde intermediate toward PIC over 
non-enzymatic synthesis of the neurotoxin quinolinic acid (QUIN) (Fig. 2). TRP catabolism via the KP 
reputedly accounts for greater than 95% of the daily TRP turnover in the CNS.4 While a clear 
understanding of the physiological role of various KP metabolites and overall pathway dynamics remains 
elusive, at least a portion of TRP is converted to the essential pyridine nucleotide, nicotinamide adenine 
dinucleotide (NAD).5,6
Alan Mehler7 was the fi rst to postulate that PIC was a metabolic product of the KP. Having identifi ed 
that an enzymatic reaction perturbed the formation of PIC away from the synthesis of QUIN, Mehler 
questioned whether; a) PIC was a normal metabolic product of TRP with some physiological function 
and b) PIC production had some effect on NAD synthesis. While research has confi rmed that PIC is a 
metabolite of the KP and knowledge of other aspects of the pathway has grown considerably over recent 
years, the salient endogenous function of PIC remains elusive, with its effect on NAD metabolism and 
signifi cance in the CNS yet to be determined.
Alterations in KP metabolism have been implicated in the pathophysiology of a variety of CNS infl am-
matory diseases including; Alzheimer’s disease,8–10 Multiple Sclerosis,11 Parkinson’s,12 Cerebral Malaria,13 
Amyotropic lateral sclerosis14 and HIV infection.15 It is therefore reasonable to consider whether changes 
in PIC levels also correlate with either cellular or clinical pathology in any of these conditions.
In this review we discuss the potential physiological action of PIC identifi ed by previous studies and 
place these fi ndings within the context of both relevance to physiological conditions and associated KP 
metabolism. Discrepancies and gaps in our current knowledge of PIC are identifi ed and areas of research 
that may promote a more complete understanding of PIC’s endogenous function are suggested.
Physical Properties of PIC
Picolinic acid is a six-membered ring structure and isomer of nicotinic acid, containing fi ve carbon 
atoms a nitrogen and a carboxyl group at position 2.
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A number of synonyms exist for picolinic 
acid including, Pyridine-2-carboxylic Acid; 
2-Pyridinecarboxylic acid; o-Pyridinecarboxylic 
Acid and alpha-Pyridinecarboxylic Acid. As a pure 
crystal, PIC has a melting point at ~137 oC and is 
soluble in water to 887 g/l. The partial molal 
volume of PIC at infi nite dilution is 83.8 ml mole, 
calculated from the density of its aqueous solutions. 
The refractivity at infi nite dilultion is 31.9 ml mole. 
Picolinic acid exists mainly in the zwitterion form 
in solution and displays relatively high viscosities 
where a 48% solution has about the same 
viscosity as a 38% sucrose solution at the same 
temperature.16
The most widely researched physical 
characteristic of picolinic acid is its efficient 
chelator properties. Chelator activity for PIC was 
fi rst reported by Weidel in 1879, where PIC was 
shown to effi ciently chelate both copper and iron. 
Later Suzuki et al17 in 1957 reported its effi cient 
chelation of a range of metals including Ni, Zn, 
Cd, Pb and Cu.
Capitalizing on its chelation properties 
PIC-metal complexes are now widely used as a 
means of introducing bioactive metals into 
biological systems. In particular, as the element 
chromium appears to play a role in carbohydrate 
and lipid metabolism, dietary supplementation 
with chromium picolinate has been advocated in 
type 2 diabetes.18 As chromium is not assimilated 
particularly well from the diet more effective 
absorption is achieved through the ingestion of a 
PIC-chromium chelate. Chromium picolinate 
[Cr(pic)(3)] supplementation reportedly has 
effects on blood glucose and lipid metabolism and 
body composition.18 In these formulations PIC is 
generally considered the non-active ingredient that 
helps solubilise the metal through the formation 
of the chelate complex.
Biological Synthesis 
of Picolinic Acid
TRP can be metabolised through oxidative 
degradation via the kynurenine pathway (KP) 
to one of three main end products; kynurenic 
acid (KYNA), PIC and NAD (Fig. 2). The KP 
begins with the oxidative cleavage of the 
amino acid tryptophan by either of the two 
enzymes indoleamine 2,3-dioxygenase (IDO; 
EC 1.13.11.17) or tryptophan 2,3-dioxygenase 
a lso cal led t ryptophan pyrolase  (TDO; 
EC 1.13.11.11) to produce formylkynurenine 
(Fig. 2). Both IDO and TDO are haem-requiring 
enzymes and are considered rate limiting for 
this pathway.
TDO is found predominantly in mammalian 
liver and can be induced by a number of factors 
including fasting, glucocorticoids, hydrocorti-
sone, L-tryptophan and nicotinic acid.19,20 In 
contrast IDO is found mainly in extrahepatic 
tissues including brain, placenta, spleen, lung, 
kidney, alimentary tract and epididymis.20,21 
Unlike TDO, IDO does not contain an activating 
site for tryptophan analogues22 and is induced 
primarily by the proinflammatory cytokine 
IFN-γ. IDO also uses the reactive oxygen inter-
mediate (ROI) superoxide as opposed to molec-
ular oxygen as a cofactor.22 TDO also differs 
from IDO in regard to substrate specificity. 
TDO uses L-tryptophan exclusively as sub-
strate whereas IDO can metabolise both L and 
D-tryptophan as well as serotonin and other 
related indoleamines.23
N
O
OH N
O
OH
a) b)
Figure 1. Chemical structures of the isomers Picolinic acid a) and Nicotinic acid b).
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In the process of PIC synthesis tryptophan
i s  ca t abo l i sed  th rough  kynuren ine  to 
3-hydroxyanthranilic acid. This is then further 
acted upon by the enzyme 3-hydroxyanthranilic 
acid oxygenase (3HAO; EC 1.13.11.6), an 
enzyme present in both cytosol and synaptosomal 
fractions24 to produce the intermediate 2-amino-
3-carboxymuconic semialdehyde (Fig. 2).
The rate limiting enzyme for PIC production 
amino-ß-carboxymuconate-semialdehyde-
decarboxylase (ACMSD; EC 4.1.1.45) will 
preferentially convert this intermediate to 
2-aminomuconic semialdehyde with subsequent 
non-enzymatic conversion to picolinic acid.25 Non 
enzymatic rearrangement of the intermediate 
occurs when ACMSD is saturated with substrate26 
allowing the production of quinolinic acid 
(QUIN). It has been suggested that under normal 
conditions these two pathways control equal 
fl ux.27 ACMSD is therefore a key enzyme direct-
ing KP metabolism towards PIC production, and 
is expressed at a ratio of 1300 : 30 : 1 in kidney, 
liver and brain, respectively.28 Not surprisingly 
the activity of ACMSD has been shown to be 
inversely proportional to the amount of NAD 
synthesised from tryptophan.25
Physiological Role of KP 
Metabolism
In the periphery, the role of the KP appears to be 
primarily directed toward the production of NAD, 
with other KP metabolites excreted unchanged in 
high concentrations in the urine.29 In the CNS, 
however, the purpose of KP activation is less clear. 
Generation of NAD is integral to brain function 
and may be derived de novo from tryptophan.6 
However, KP activation potentially occurs in all 
brain cell types, including neurons,10 astrocytes,30 
infi ltrating macrophages,31 dendritic cells32 and 
blood brain barrier (BBB) endothelial cells.33 
With many kynurenines (the collective term for 
KP metabolites) showing neuro-modulatory func-
tion in the CNS it is unclear at what point synthe-
sis and release of various kynurenines change 
from being part of normal physiological processes 
to becoming contributors to pathophysiological 
activity.
2-amino-3-
carboxymuconate
-6-semialdehyde 
Kynurenine-3-hydroxylase 
(3HAO) 
anthranilic acid 
L-tryptophan 
Kynurenine 
formylkynurenine 
3-hydroxykynurenine 
3-hydroxy-anthranilic acid 
Quinolinic acid 
Kynurenic acid 
NAD
2-amino-3-carboxymuconate-
semialdehyde decarboxylase 
(ACMSD) 
Non-enzymatic
Indoleamine-2,3-
dioxygenase (IDO) 
Kynurenine formamidase 
Kynurenine 
aminotransferase (KAT) 
Kynureninease (Kynase) 
Quinolinic acid 
phosphoribosyl transferase 
(QPRT) 
3-hydroxyanthranilic acid 
oxygenase (3HAO) 
Picolinic acid 
Tryptophan 2,3-
dioxygenase (TDO) 
Figure 2. The kynurenine pathway in the CNS.
74
Grant et al
International Journal of Tryptophan Research 2009:2 
Quinolinic acid (QUIN) and KYNA are two 
neuroactive KP metabolites that have received 
considerable attention for their modulation of the 
excitatory amino acid N-methyl-D-aspartate 
(NMDA) receptor. While QUIN shows neurotoxic 
effects by over activation of the NMDA receptor, 
KYNA offers neuro-protection by blocking 
receptor function via an allosteric glycine site.34 
Emphasis has, therefore, been placed upon the 
importance of maintaining a balanced ratio between 
these two metabolites.
Often overlooked however, is the observation 
that PIC also shows antagonistic properties 
towards the toxic effects of QUIN via an unknown 
mechanism.35,36 PIC’s role in maintaining the 
balance between neurotoxic and neuro-protective 
KP metabolites requires further investigation.
Experimental Actions of PIC: 
In vitro and In vivo
On its own, in experimental systems, PIC is 
reported to elicit a number of potential effects 
within the body, particularly involving immune 
function and antimicrobial activity.
In vitro studies suggest that PIC (at supernatant 
concentrations of 1–4 mM) can enhance 
macrophage effector functions through the 
enhancement of interferon-γ (INFγ) dependant 
nitric oxide synthase (NOS) gene expression37,38 
and induce expression of the macrophage 
infl ammatory proteins (MIP)1α and 1β.39 While 
the mechanism producing the synergism with 
IFN-γ is not known PIC mediated induction of 
MIP 1α and β is thought to be through an iron 
chelation dependant process.
High PIC concentrations (1–4 mM) have also 
been reported to selectively inhibit a variety of 
viruses in culture including the Human Immuno-
deficiency virus (HIV), Herpes Simplex virus 
(HSV), and Simian virus (SV) in culture.40,41 PIC 
appears to produce its antiviral activity through an 
initial cytotoxic action which in turn increases 
apoptosis of infected cells and a reduction in viral 
replication.41 PIC in combination with IFNγ has 
also been shown to inhibit retroviral expression of 
the J2 retrovirus,42 again through an unknown 
mechanism.
Anti-microbial effects of PIC (2.5–40 mM) have 
been observed against Mycobacterium avium 
complex (MAC), with signifi cant enhancement of 
the antimicrobial action of the drugs clarithromycin, 
rifampin and various fl uoroquinolones.43,44 It is 
suggested that as PA effi ciently chelates metal ions, 
such as Zn2+ and Fe2+ it is therefore likely that its 
antimicrobial activity against MAC organisms is 
due to its ability to chelate essential metal ions such 
as Fe2+. 43
Some investigators have also observed an effect 
of PIC on tumour growth. In vivo studies on mice 
inoculated with MBL-2 lymphoma cells showed 
that those treated with injections of PIC (100 mg/Kg) 
in combination with activated macrophages, had 
significant increases in lifespan compared to 
control.45 These effects are arguably due to 
macrophage activation mechanisms through IFN-γ 
mediated mechanisms as suggested previously.45
Importantly high concentrations of PIC, relative 
to physiological levels, were used in all of the 
investigations discussed above. Tables 1 and 2 
highlight the large discrepancy between PIC 
concentrations used experimentally in vitro/in vivo 
Table 1. PIC concentrations used experimentally.
Reported physiological effects of PIC [PIC] used Reference
Induces MIP 1 α & β expression1 4000 μM 39
Enhances IFN-γ mediated NO production1 4000 μM 37
Anti-tumour activity2 100 mg/kg 45
Anti-viral: SV-transformed cells1 1000–3000 μM 40
Anti-viral: HIV infected cells1 1500–3000 μM 40
Anti-viral: J2 retrovirus1 4000 μM 42
Anti-microbial: against MAC 2500–20000 μM 43
complex1 2500–40000 μM 44
Experiment performed using; 1cell culture, 2whole animal (mouse).
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(Table 1) and reported levels of endogenous PIC 
(Table 2). With PIC concentrations in vivo generally 
ranging within the low to mid nano (10−9) molar 
range the milimolar (10−3) concentrations used in 
the above cited studies have generally resulted in 
an approximately one million fold difference 
between physiological and experimental PIC con-
centrations. While these studies do indicate 
possible therapeutic roles for PIC, the large 
discrepancy between endogenous and experimental 
PIC levels does raise a question over the relevance 
of these observations to the natural physiological 
function of PIC.
PIC Concentrations in Diseases 
of the CNS
An often useful aid to understanding the 
physiological role of an uncharacterised bio-
logical molecule is the study of changes in the 
endogenous levels of the molecule in health and 
disease. Current literature in this area is however 
limited to a report by Medana et al.13 showing 
raised PIC levels in the CSF of patients with 
cerebral malaria and a recent report from our own 
group in which no signifi cant difference in PIC 
levels were identifi ed between different CNS 
disease categories.46 Importantly we have shown 
that any attempt at correlating PIC levels in the 
CNS may be complicated by an apparent diurnal 
fl uctuation in CSF PIC levels as discussed later 
in this review.
As PIC is part of a more complex pathway, it is 
relevant to review how other kynurenines are 
affected by disease and under what conditions 
altered levels have been observed (for summary 
see Table 3).
It has been suggested that altered KP metabo-
lism contributes signifi cantly to the pathophysio-
logy of neurodegenerative and inflammatory 
disorders of the CNS.34 Lower levels of KYNA 
and the enzymes involved in its production have 
been found in the plasma, CSF and erythrocytes of 
Parkinson’s and Alzheimer’s disease sufferers.9,47,48 
On the other hand, Huntington’s disease subjects 
exhibited elevated cortical QUIN levels in the early 
stages of disease onset, suggesting excitotoxicity 
as the cause of later neurodegeneration.49
Various viral infections show an up regulation 
of the entire KP. HIV infection exhibits increased 
levels of both QUIN and TRP in the human brain,50 
while in the CSF, QUIN has been further correlated 
to worsening brain atrophy.51 Poliovirus infected 
macaques showed increases of CSF QUIN, KYNA, 
L-kynurenine, kynurenine-3-hydroxylase, and 
kynureninase activities, with the magnitude of 
increase correlating with the severity of observed 
motor defi cits.52
In a study of African children suffering 
from cerebral malaria elevated PIC and QUIN 
concentrations predicted a fatal outcome to the 
disease.13 These observations are consistent with 
results reported in an animal model using centrally 
infected (Plasmodium berghei) mice, where CSF 
PIC also increased markedly with malarial 
infection.53
While some studies have shown that immune 
activation can result in elevated PIC levels37–39 a 
recent study by our group failed to find any 
correlation between CSF PIC concentrations and 
CNS disease states.46 This data was generated from 
a population of 241 patients that were suspected 
of meningitis as well as other nervous system dis-
orders. Immune activation markers such as white 
cell count and C-reactive protein also did not show 
any correlation with CSF PIC concentrations.
These results led us to investigate whether other 
biological factors may infl uence the production of 
PIC in the CNS.
Biological Factors Infl uencing PIC 
Levels in the CNS
We have recently reported that CSF PIC levels in 
the CNS may be infl uenced by both the age of the 
subject and time of sample collection.46 This obser-
vation has not been previously reported, although 
other studies have noted similar patterns for other 
Table 2. Endogenous concentrations of PIC.
Reported endogenous PIC locations [PIC] (μM) Reference
Plasma 0.299 +/− 0.034 8
Brain (cortical tissue) 0.100–0.150 8
CSF (no brain injury) 0.017 +/− 0.005 8
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kynurenines. In a population without detectable 
neurological disease Kepplinger et al.54 and Heyes 
et al.9 observed that CSF KYNA levels signifi  cantly 
increased with advancing age. Consistent with our 
observation, the activity of the PIC producing 
enzyme ACMSD has been shown to increase 
with age in studies of rat kidney, liver and small 
intestine.55 Unfortunately, an investigation of age-
associated changes in ACMSD activity in human 
tissue is yet to be reported.
From a sample of subjects with no apparent 
CNS disease, we observed that CSF PIC concen-
trations display a signifi cant diurnal variation 
depending on the time of sample collection.46 
Importantly, QUIN levels did not show this diurnal 
pattern, thus making the observation unique to PIC 
alone and suggesting the diurnal variation in 
ACMSD activity is most likely caused by substrate 
availability. Further, this circadian fl uctuation was 
not observed in CSF PIC levels from patients with 
apparent CNS disease, suggesting that this 
temporal rhythm in PIC concentrations can be 
signifi cantly perturbed during times of immune 
activation.
This observed diurnal fl uctuation is remarkably 
similar to a serial CSF sampling study of 12 healthy 
volunteers by Kennedy and colleagues.56 A signi-
fi cant diurnal pattern in CSF TRP metabolism was 
observed, with low TRP levels at near noon, and 
a maximum reached at 11 pm—midnight.56 
From this, it was proposed that the peak to trough 
availability of TRP as a precursor molecule may 
be of sufficient magnitude to influence other 
metabolite processes, such as melatonin secretion, 
which also follows a diurnal cycle.56
With a diurnal fl uctuation modelled by varia-
tions in TRP levels, it can be proposed that the 
availability of TRP in the CSF has a direct affect 
on substrate availability for CNS PIC production.
Future studies are required to establish what 
conditions affect the baseline diurnal fl uctuation 
of CSF PIC and what pathophysiological/disease 
states may be linked to these changes.
Enzymatic Control of PIC 
Production: ACMSD
As the availability of substrate will impact the 
synthesis of PIC in the CNS,56 it is relevant to 
consider whether the activity of surrounding meta-
bolic enzymes could also infl uence PIC levels.
ACMSD activity will be influenced by the 
availability of its relevant substrate which in turn 
is dependant on fl ux through the KP. The activity 
of IDO, the rate limiting enzyme of the KP, (Fig. 2) 
is therefore positioned to signifi cantly infl uence 
the synthesis of the PIC precursor.
IDO activity has been shown to be involved in a 
variety of physiological processes. IDO activation 
can influence maternal tolerance toward the 
allogenic fetus57 regulate autoimmune disorders,58 
and suppress transplant rejection.59 Inhibitors of 
this enzyme are, therefore, currently being 
developed for cancer immunotherapy.60
Table 3. Altered Kynurenine pathway metabolites in disease.
CNS disease Alteration of kynurenines in the CNS 
(CSF/brain tissueΨ)
Reference
QUIN KYNA PIC
Alzheimer’s nt nt n/sΨ 8
nt Ð nt 9
Parkinson’s nt Ð nt 12
Multiple sclerosis ÏΨ Ð nt 11
Huntington’s Ï nt nt 49
Cerebral Malaria Ï Ï Ï 13
HIV infection nt Ï nt 52
Down Syndrome nt ÏΨ nt 72
Amyotrophic nt Ï nt 73
lateral sclerosis Ï nt nt 14
Ï = Elevated levels compared to control, Ð = decreased levels compared to control.
Abbreviations: nt, not tested, n/s, not signifi cant.
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While the mechanism through which IDO 
displays its immune activity appears to involve 
tryptophan concentrations in the microenvironment57 
the infl uence of downstream metabolites such as 
PIC on these and other activities has not been 
extensively investigated.
As ACMSD substrate required for PIC synthesis 
is dependant on IDO activity, any therapeutic 
manipulation of IDO will affect the synthesis of 
PIC. Understanding the pathophysiological role of 
PIC may help prevent potential PIC associated side 
effects following IDO inhibition.
The position of ACMSD within the KP 
establishes it as the rate limiting enzyme for PIC 
synthesis (Fig. 2). Interestingly, a number of 
nutritional factors and hormonal effects have been 
observed to alter the activity of this enzyme.
High protein diets, the diabetic condition61 and 
increased glucocorticoids62 have all been 
demonstrated to increase the activity of ACMSD. 
Whereas high levels of dietary polyunsaturated 
fatty acids,63 peroxisome-proliferators64 and the 
environmental plasticizer contaminants, phthalate 
esters65 appear to significantly down-regulate 
the activity of this enzyme.
While the physiological rationale for these 
changes is not known, high protein diets have 
previously been shown to also increase enzymes 
associated with energy metabolism.66 Is it possible 
that ACMSD/PIC may play a role in the regulation 
glucose/energy metabolism? It is relevant to note 
that a number of metallopicolinate complexes have 
been found with insulinomimetic activity where 
the presence of the picolinate signifi cantly enhances 
the insulin sensitising activity.67
Importantly most studies in this area have 
measured the activity of ACMSD from the 
peripheral tissue of animal models. Peripheral 
tissue data may or may not correlate substantially 
with the centrally located human protein which 
apparently has a relatively low level of expression.28 
The lack of relevant experimental data relating to 
the human CNS highlights the need for future 
research in this area.
PIC and the BBB
The measurement of PIC in the CSF is assumed to 
refl ect endogenous PIC production within the CNS 
alone. However it is also possible that CSF levels 
may be infl uenced by transfer of PIC from the 
peripheral circulation.
Chromium picolinate is an established dietary 
supplement used to treat conditions of insulin 
resistance.18 The ability of this complex to produce 
affects within the CNS has been queried.68 Aggett 
et al.69 reported that divalent metal complexes of 
PIC do not readily pass through lipid bilayers. PIC 
itself also has a relatively low partition coeffi cient 
(logP = 0.098a) refl ecting its low solubility in a 
lipophilic medium. This makes it unlikely that PIC 
would pass through the BBB on its own. In addi-
tion, Smythe and colleagues8 reported that PIC 
plasma levels were at concentrations 3–15 times 
higher than those in the brain tissue and CSF 
(Table 2). For such a concentration ratio to be 
maintained, it is thought that limited fl ux of PIC 
occurs between the CNS and the periphery.
While the above observations indicate that CSF 
PIC levels refl ect PIC synthesis within the CNS, 
other KP metabolites may contribute signifi cantly 
to their respective cerebral pools.
In experiments using in situ brain perfusion 
techniques on rats, L-kynurenine and 3-hydroxykyn-
urenine were found to be taken up into the brain at 
signifi cant rates across the BBB via the large amino 
acid transporter.70 Owe-Young and colleagues33 
recently found that KP activation occurs in BBB 
endothelial cells, and when treated with INFγ, 
increased the expression of kynurenine but not 
QUIN or PIC. That these metabolites contribute to 
PIC production through increased substrate avail-
ability has been proposed but never tested.71 It 
would be benefi cial to our understanding in this 
area if future studies examined the concentra-
tion of PIC in the CNS under conditions of both 
peripheral KP supplementation and peripheral KP 
activation.
In summary, there are a number of biological 
factors that can potentially affect PIC levels and 
synthesis in the CNS including; age and circadian 
rhythms and hormonal and nutritional factors.
However the physiological role(s) of PIC within 
the CNS is not well understood. Improved under-
standing may be achieved by characterizing the 
changes to cell/organ biochemistry/physiology at 
PIC concentrations within acceptable physiologi-
cal concetrations. In addition, it has not been 
established whether there is a link between 
PIC concentration and any disease state. 
Whether PIC production is as clearly connected to 
aLog P calculated by Advanced Chemical Development log P Batch 
version 100 software.
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pathophysiological changes as other kynurenines 
such as QUIN and KYNA requires further inves-
tigation with careful attention to the confounding 
effects of age and diurnal rhythm.
Disclosure
The authors report no confl icts of interest.
References
 1. Dazzi, C, Candiano G, Massazza S, Ponzetto A, Varesio L. New high-
performance liquid chromatographic method for the detection of pico-
linic acid in biological fl uids. J Chromatogr. 2001;751:61–8.
 2. Smythe GA, Braga O, Brew BJ, et al. Concurrent Quantifi cation of 
Quinolinic, Picolinic, and Nicotinic Acids Using Electron-Capture 
Negative-Ion Gas Chromatography Mass Spectrometry. Anal Biochem. 
2002;301:21–6.
 3. Rebello T, Lonnerdal B, Hurley LS. Picolinic acid in milk, pancreatic 
juice, and intestine: inadequate for role in zinc absorption. Am J Clin 
Nutr. 1982;35:1–5.
 4. Peters JC. Tryptophan nutrition and metabolism: an overview. Adv Exp 
Med Biol. 1991;294:345–58.
 5. Grant RS, Passey R, Matanovic G, Smythe G, Kapoor V. Evidence for 
Increased de Novo Synthesis of NAD in Immune-Activated RAW264.7 
Macrophages: A Self-Protective Mechanism? Arch Biochem Biophys. 
1999;372:1–7.
 6. Grant R, Kapoor V. Inhibition of indoleamine 2,3-dioxygenase activity 
in IFN-[gamma] stimulated astroglioma cells decreases intracellular 
NAD levels. Biochem Pharmacol. 2000;66:1033–6.
 7. Mehler AH. Formation of picolinic and quinolinic acids following 
enzymatic oxidation of 3-hydroxyanthranilic acid. J Biol Chem. 
1956;218(1):241–54.
 8. Smythe GA, Poljak A, Bustamante S, et al. ECNI GC-MS analysis of 
picolinic and quinolinic acids and their amides in human plasma, CSF, 
and brain tissue. Adv Exp Med Biol. 2003;527:705–12.
 9. Heyes M, Saito K, Crowley J, et al. Quinolinic acid and kynurenine 
pathway metabolism in infl ammatory and noninfl ammatory neuro-
logical disease. Brain. 1992;115:1249–73.
10. Guillemin GJ, Smythe G, Takikawa O, Brew BJ. Expression of indole-
amine 2,3-dioxygenase and production of quinolinic acid by human 
microglia, astrocytes, and neurons. Glia. 2005;49:15–23.
11. Rejdak K, Bartosik-Psujek H, Dobosz B, et al. Decreased level of 
kynurenic acid in cerebrospinal fl uid of relapsing-onset multiple scle-
rosis patients. Neurosci Lett. 2002;4; 331(1):63–5.
12. Hartai Z, Juhasz A, Rimanoczy A. et al. Decreased serum and red blood 
cell kynurenic acid levels in Alzheimer’s disease. Neurochem Int. 
2007;50:308–13.
13. Medana IM, Day NPJ, Salahifar-Sabet H. et al. Metabolites of the 
kynurenine pathway of tryptophan metabolism in the cerebrospinal 
fl uid of Malawian children with malaria. J Infect Dis. 2003;188:
844–9.
14. Guillemin G J, Meininger V, Brew BJ. Implications for the kynurenine 
pathway and quinolinic acid in amyotrophic lateral sclerosis. Neuro-
degener Dis. 2005;2:166–76.
15. Heyes MP, Brew BJ, Martin A. et al. Quinolinic acid in cerebrospinal 
fl uid and serum in HIV-1 infection: relationship to clinical and neuro-
logical status. Ann Neurol. 1991;29:202–9.
16. Robinson RA, Green RW. Some Physical Properties of Aqueous Pico-
linic Acid Solutions J Phys Chem. 1961;65(6):1084.
17. Suzuki K, Yasuda M, Yamasaki K. Stability constants of picolinic and 
quinaldic acid chelates of bivalent metals. J Phys Chem. 1957;61:
229–31.
18. Broadhurst CL, Domenico P. Clinical studies on chromium picolinate 
supplementation in diabetes mellitus—a review. Diabetes. Technol. 
Ther. 2006;8:677–87.
19. Sainio E, Sainio P. Comparison of effects of Nicotinic acid or 
Tryptophan on tryptophan 2,3-dioxygenase in acute and chronic stud-
ies. Toxicol Appl Pharmacol. 1990;102:251–8.
20. Yoshida R, Nukiwa T, Watanabe Y, Fujiwara M, Hirata F, Hayaishi O. 
Regulation of indoleamine 2,3-dioxygenase activity in the small intes-
tine and the epididymis of mice. Archiv Biochem Biophys. 1980;203:
343–51.
21. Yamazaki F, Kuroiwa T, Takikawa O, Kido R. Human indolamine 
2,3-dioxygenase. Its tissue distribution, and characterization of the 
placental enzyme. Biochem J. 1985;230:635–8.
22. Botting NP. Chemistry and Neurochemistry of the Kynurenine pathway 
of Tryptophan metabolism. Chemical Society Reviews 1995;401–12.
23. Ishimura Y, Nozaki M, Hayaishi O. The oxygenated form of 
L-tryptophan 2,3-dioxygenase as reaction intermediate. J Biol Chem. 
1970;245:3593–602.
24. Saito K, Markey SP, Heyes MP. Effects of immune activation on 
quinolinic acid and neuroactive kynurenines in the mouse. Neurosci-
ence. 1992;51:25–39.
25. Ikeda M, Tsuji S, Nakamura S, Ichiyama A, Nishuzuka Y, Hayaishi O. 
Studies on the biosynthesis of nicotinamide adenine dinucleotide. ii. 
A role of picolinic carboxylase in the biosynthesis of nicotinamide 
adenine dinucleotide from tryptophan in mammals. J Biol Chem. 
1965;240:1395–401.
26. Bender DA, McCreaner GM. Kynurenine hydroxylase: a potential rate 
limiting enzyme in tryptophan metabolism. Biochemical Society Trans-
actions. 1985;13:441–3.
27. Salter M, Knowles RG, Pogson CI. Quantifi cation of the importance 
of individual steps in the control of aromatic amino acid metabolism. 
Biochem J. 1986;234:635–47.
28. Pucci L, Perozzi S, Cimadamore F, Orsomando G, Raffaelli N. Tissue 
expression and biochemical characterization of human 2-amino 3-car-
boxymuconate 6-semialdehyde decarboxylase, a key enzyme in tryp-
tophan catabolism. FEBS J. 2007;274:827–40.
29. Schwarcz R, Pellicciari R. Manipulation of brain kynurenines: glial 
targets, neuronal effects, and clinical opportunities. J Pharmacol Exp 
Ther. 2002;303:1–10.
30. Guillemin GJ, Kerr SJ, Smythe GA, et al. Kynurenine pathway 
metabolism in human astrocytes: a paradox for neuronal protection. 
J Neurochem. 2001;78: 842–53.
31. Heyes MP, Achim CL, Wiley CA, Major EO, Sato K, Markey SP. Human 
microglia convert l-tryptophan into the neurotoxin quinolinic acid. 
Biochem J. 1996;320:595–7.
32. Hwu P, Du MX, Lapointe R, Do M, Taylor M W, Young HA. Indoleamine 
2,3-dioxygenase production by human dendritic cells results in the inhibi-
tion of T cell proliferation. J Immunol. 2000;164:3596–9.
33. Owe-Young R. Webster NL, Mukhtar M, et al. Kynurenine pathway 
metabolism in human blood-brain-barrier cells: implications for immune 
tolerance and neurotoxicity. J Neurochem. 2008;105:1346–57.
34. Jhamandas KH, Boegman RJ, Beninger RJ, Miranda AF, Lipic KA. 
Excitotoxicity of quinolinic acid: modulation by endogenous antago-
nists. Neurotox Res. 2000;2:139–155.
35. Beninger RJ, Colton AM, Ingles JL, Jhamandas K, Boegman RJ. 
Picolinic acid blocks the neurotoxic but not the neuroexcitant properties 
of quinolinic acid in the rat brain: evidence from turning behaviour and 
tyrosine hydroxylase immunohistochemistry. Neurosci Res. 
1994;61:603–12.
36. Cockhill J, Jhamandas K, Boegman RJ, Beninger RJ. Action of picolinic 
acid and structurally related pyridine carboxylic acids on quinolinic 
acid-induced cortical cholinergic damage. Brain Res. 1992;599:
57–63.
37. Melillo G, Cox GW, Biragynn A, Sheffl er LA, Varesiot L. Regulation 
of Nitric-oxide Synthase mRNA Expression by Interferon-y and Pico-
linic Acid. J Biol Chem.1994;269:8128–33.
38. Varesio L, Clayton M, Blasi E, Ruffman R, Radzioch  D. Picolinic acid, 
a catabolite of tryptophan, as the second signal in the activa-
tion of IFN-y-primed macrophages. J Immunol. 1990;145:
4265–71.
79
The physiological action of picolinic acid in the human brain 
International Journal of Tryptophan Research 2009:2 
39. Bosco MC, Rapisarda A, Massazza S, Melillo G, Young H, Varesio L. 
The Tryptophan Catabolite Picolinic Acid Selectively Induces the 
Chemokines Macrophage Inflammatory Protein-1a and -1b in 
Macrophages. J Immunol. 2000;164:3283–91.
40. Fernandez-Pol JA, Johnson GS. Selective toxicity induced by picolinic 
acid in simian virus 40-transformed cells in tissue culture. Cancer Res. 
1977;37:4276–9.
41. Fernandez-Pol JA, Klos DJ, Hamilton PD. Antiviral, cytotoxic and 
apoptotic activities of picolinic acid on human immunodefi ciency 
virus-1 and human herpes simplex virus-2 infected cells. Anticancer 
Res. 2001;21:3773–6.
42. Blasi E, Radzioch D, Varesio L. Inhibition of Retroviral mRNA expres-
sion in the murine macrophage cell line GG2EE by biological response 
modifi ers. J Immunol. 1988;141:2153–7.
43. Cai S, Sato K, Shimizu T, Yamabe S, Hiraki M, Sano C, Tomioka H. 
Antimicrobial activity of picolinic acid against extracellular and intra-
cellular Mycobacterium avium complex and its combined activity with 
clarithromycin, rifampicin and fl uoroquinolones. J Antimicrob Che-
mother. 2006;57:85–93.
44. Shimizu T, Tomioka H. Activity of Picolinic Acid in Combination with 
the Antiprotozoal Drug Quinacrine against Mycobacterium avium 
Complex. Antimicrob Agents Chemother. 2006;50:3186–8.
45. Ruffman R, Schlick R, Chirigos MA, Budzynsky W, Varesio, L. Anti-
proliferative activity of picolinic acid due to macrophage activation. 
Drugs Exp Clin Res. 1987;13:604–14.
46. Coggan SE, Smythe GA, Bilgin A, Grant RS. Age and circadian infl u-
ences on picolinic acid concentrations in human cerebrospinal fl uid. 
J Neurochem. 2009;08:1220–5.
47. Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L. Kynurenine 
metabolism in plasma and in red blood cells in Parkinson’s disease. 
J Neurol Sci. 2005b;239:31–5.
48. Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L. Kynurenine 
metabolism in multiple sclerosis. Acta Neurol Scand. 2005a; 
112:93–6.
49. Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R. Neostriatal and 
cortical quinolinate levels are increased in early grade Huntington’s 
disease. Neurobiol Dis. 2004;17:455–61.
50. Brown R, Ozaki S, Datta S, Borden E, Sondel P, Malone D.  Implications 
of interferon-induced tryptophan catabolism in cancer, auto-immune 
diseases and AIDS. Adv Exp Med Biol. 1991;294:425–35.
51. Heyes MP, Ellis RJ, Ryan L, et al. Elevated cerebrospinal fl uid quino-
linic acid levels are associated with region-specifi c cerebral volume 
loss in HIV infection. Brain. 2001;124:1033–1042.
52. Heyes MP, Saito K, Major EO, Milstien SP, Vickers JH. A mechanism 
of quinolinic acid formation by brain in infl ammatory neurological 
disease.  Attenuation of synthesis from L-tryptophan by 
6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate. Brain Res. 
1993;116(Pt 6):1425–50.
53. Clark CJ, Mackay GM, Smythe GA, Bustamante S, Stone TW, 
Phillips RS. () Prolonged Survival of a Murine Model of Cerebral Malaria 
by Kynurenine Pathway Inhibition. Infect Immun. 2005;73:
5249–51.
54. Kepplinger B, Baran H, Kainz A, Ferraz-Leite H, Newcombe J, Kalina P. 
Age-related increase of kynurenic acid in human cerebrospinal 
fluid—IgG and beta2-microglobulin changes. Neurosignals. 
2005;14(3):126–35.
55. Comai S, Costa CVL, Ragazzi E, Bertazzo A, Allegri G. The effect of 
age on the enzyme activities of tryptophan metabolism along the kyn-
urenine pathway in rats. Clin Chim Acta. 2005;360:67–80.
56. Kennedy JS, Gwirtsman HE, Schmidt DE, et al. Serial cerebrospinal 
fl uid tryptophan and 5-hydroxy indoleacetic acid concentrations in 
healthy human subjects. Life Sci. 2002;71:1703–15.
57. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal 
rejection by tryptophan catabolism. Science 1998;281:1191–3.
58. Kwidzinski E, Bunse J, Aktas O, et al. Indolamine 2,3-dioxygenase is 
expressed in the CNS and down-regulates autoimmune infl ammation. 
Faseb J. 2005;19:1347–9.
59. Uyttenhove C, Pilotte L, Theate I, et al. () Evidence for a tumoral immune 
resistance mechanism based on tryptophan degradation by indoleamine 
2,3-dioxygenase. Nat Med. 2003;9:1269–74.
60. Hou DY, Muller AJ, Sharma MD, et al. Inhibition of indoleamine 
2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan 
correlates with antitumor responses. Cancer Res. 2007;67:
792–801.
61. Tanabe A, Egashira Y, Fukuoka S, et al. Expression of rat hepatic 
2-amino-3-carboxymuconate-6-semialdehyde decarboxylase is affected 
by a high protein diet and by streptozotocin-induced diabetes. J Nutr. 
2002;132:1153–9.
62. Egashira Y, Murotani G, Tanabe A, et al. Differential effects of dietary 
fatty acids on rat liver alpha-amino-beta-carboxymuconate-epsilon-
semialdehyde decarboxylase activity and gene expression. Biochim 
Biophys Acta. 2004;1686:118–24.
63. Egashira Y, Ogawara R, Ohta T, Sanada H. Suppression of rat hepatic 
a-amino-b-carboxymuconate- e-semialdehyde decarboxylase (ACMSD) 
activity by linoleic acid in relation to its induction by glucocorticoids 
and dietary protein. Biosci Biotech Biochem. 1994;58.
64. Shin M, Ohnishi M, Iguchi S, Sano K, Umezawa C. Peroxisome-
proliferator regulates key enzymes of the tryptophan-NAD+ pathway. 
Toxicol Appl Pharmacol.1999;158:71–80.
65. Fukuwatari T, Ohsaki S, Fukuoka S, Sasaki R, Shibata K. Phthalate 
Esters Enhance Quinolinate Production by Inhibiting Amino-
β-Carboxymuconate-Semialdehyde Decarboxylase (ACMSD), a Key 
Enzyme of the Tryptophan Pathway. Toxicol Sci. 2004;81: 302–308.
66. Szepesi B, Freedland RA. Time-course of changes in rat liver enzyme 
activities after initiation of a high protein regimen. J Nutr. 1968;94(4):
463–468.
67. Yasumatsu N, Yoshikawa Y, Adachi Y, Sakurai H Antidiabetic 
copper(II)-picolinate: impact of the fi rst transition metal in the metal-
lopicolinate complexes. Bioorg Med Chem. 2007;15(14):4917–22.
68. Reading SA. Chromium picolinate. J Fla Med Assoc. 1996;
83:29–31.
69. Aggett, P J, Fenwick PK, Kirk H. An In Vitro Study of the Effect of 
Picolinic Acid on Metal Translocation across Lipid Bilayers. J Nutr. 
1989;119:1432–7.
70. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR. Blood-brain 
barrier transport of kynurenines: Implications for brain synthesis and 
metabolism. J Neurochem. 1991;56:2007–2017.
71. Stone TW. Neuropharmacology of quinolinic acids and kynurenic acids. 
Pharmacol Rev. 1993;45:309–79.
72. Baran H, Cairns N, Lubec B, Lubec G. Increased kynurenic acid levels 
and decreased brain kynuenine aminotransferase in parients with downs 
syndrome. Life Sci. 1996;58:1891–9.
73. Ilzecka J, Kocki T, Stelmasiak Z, Turski WA. Endogenous protectant 
kynurenic acid in amyotrophic lteral sclerosis. Acta Neurol Scand. 
2003;107:412–8.
